To date, ONL has raised more than $4 million from a combination of early stage investors and research grants.
Most recently, ONL completed a financing of more than $1 million from both existing investors and new investors, which include Invest Michigan and the Novartis Institutes for BioMedical Research.
This funding will enable ONL to continue to make important technical progress toward the filing of an IND for ONL1204 for the treatment of retinal detachment and other key ocular indications.
To find out more about investing in ONL Therapeutics, please contact us at:
1600 Huron Pkwy
Building 520, Second Floor
Ann Arbor, MI 48109